1. Montanaro M, Latagliata R, Cedrone M, et al. 2014; Thrombosis and survival in essential thrombocythemia: a regional study of 1,144 patients. Am J Hematol. 89:542–6. DOI:
10.1002/ajh.23685. PMID:
24481665.
Article
2. Carobbio A, Thiele J, Passamonti F, et al. 2011; Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 117:5857–9. DOI:
10.1182/blood-2011-02-339002. PMID:
21490340.
Article
3. Singla A, Jagasia D, Garg M, Lowry PA, Stapleton D. 2012; Acute ST-segment elevation myocardial infarction: a rare initial presentation of previously undiagnosed essential thrombocythemia. Platelets. 23:463–6. DOI:
10.3109/09537104.2011.640966. PMID:
22686448.
Article
4. Arboix A, Besses C, Acín P, et al. 1995; Ischemic stroke as first manifestation of essential thrombocythemia. Report of six cases. Stroke. 26:1463–6. DOI:
10.1161/01.STR.26.8.1463. PMID:
7631354.
6. Enblom A, Lindskog E, Hasselbalch H, et al. 2015; High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med. 26:344–7. DOI:
10.1016/j.ejim.2015.03.009. PMID:
25863408.
Article
7. Kim Y, Oh SS, Jeong MH, et al. 2019; Comparison of short-term clinical outcomes between Resolute Onyx zotarolimus-eluting stents and everolimus-eluting stent in patients with acute myocardial infarction: results from the Korea Acute Myocardial infarction Registry (KAMIR). Cardiol J. 26:469–76. DOI:
10.5603/CJ.a2018.0053. PMID:
29745969.
Article